Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To compare the efficacy and safety of once-weekly semaglutide 1.0 mg s.c. with exenatide extended release (ER) 2.0 mg s.c. in subjects with type 2 diabetes. RESEARCH DESIGN AND METHODS: In this phase 3a, open-label, parallel-group, randomized controlled trial, 813 subjects with type 2 diabetes taking oral antidiabetic drugs were randomized (1:1) to semaglutide 1.0 mg or exenatide ER 2.0 mg for 56 weeks. The primary end point was change from baseline in HbA1c at week 56. RESULTS: Mean HbA1c (8.3% [67.7 mmol/mol] at baseline) was reduced by 1.5% (16.8 mmol/mol) with semaglutide and 0.9% (10.0 mmol/mol) with exenatide ER (estimated treatment difference vs. exenatide ER [ETD] –0.62% [95% CI –0.80, –0.44] [–6.78 mmol/mol (95% CI –8.70, –4.86)]; P < 0.0001 for noninferiority and superiority). Mean body weight (95.8 kg at baseline) was reduced by 5.6 kg with semaglutide and 1.9 kg with exenatide ER (ETD –3.78 kg [95% CI –4.58, –2.98]; P < 0.0001). Significantly more subjects treated with semaglutide (67%) achieved HbA1c <7.0% (<53 mmol/mol) versus those taking exenatide ER (40%). Both treatments had similar safety profiles, but gastrointestinal adverse events were more common in semaglutide-treated subjects (41.8%) than in exenatide ER–treated subjects (33.3%); injection-site reactions were more frequent with exenatide ER (22.0%) than with semaglutide (1.2%). CONCLUSIONS: Semaglutide 1.0 mg was superior to exenatide ER 2.0 mg in improving glycemic control and reducing body weight after 56 weeks of treatment; the drugs had comparable safety profiles. These results indicate that semaglutide treatment is highly effective for subjects with type 2 diabetes who are inadequately controlled on oral antidiabetic drugs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“None of the current DM medications associated with weight loss, including GLP-1 RAs and SGLT2is, have resulted in more than 5.6% weight loss in clinical trials, and this includes dulaglutide,765 exenatide,766 exenatide-ER,767 liraglutide 1.8 mg,768 lixisenatide,769 semaglutide 1.0 mg/week,770,771 semaglutide 1.0 mg/week added to SGLT2i,772 oral semaglutide 14 mg,773 canagliflozin,774 dapagliflozin”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [766]
In the citing paper
“Study designs for these double-blind, randomized controlled trials have been published previously [18–21].”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [18]
In the citing paper
“Semaglutide by subcutaneous injection was shown to be superior to exenatide once weekly, dulaglutide, and liraglutide in lowering HbA1c.19”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [19]
In the citing paper
“Serum calcitonin was measured during these trials, and no notable difference in mean levels was seen between the treatment arms.”
From Safety of Semaglutide (2021) · cites this paper as [22]
In the citing paper
“None of these were medullary carcinoma.”
From Safety of Semaglutide (2021) · cites this paper as [22]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.
Flint, A., Raben, A., Astrup, A., & Holst, J. J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci990 · Cited by 1,402 · cited 1×
“GLP-1 RAs also reduce body weight by inducing feelings of satiety and fullness and reducing feelings of hunger, thereby lowering energy intake (3,4).”
BackgroundSeaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 2×
“mology to native human GLP-1 and is structurally similar to liraglutide (10), but important structural modifications make it less susceptible to degradation by dipeptidyl peptidase-4 and increase its specific high-affinity binding to albumin (10).”
BackgroundDeclaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects
World Medical Association (WMA) (2009) · Jahrbuch für Wissenschaft und Ethik · doi:10.1515/9783110208856.233 · Cited by 1,087
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
Cited by
Items 401–500 of 657
The effect of GLP-1 receptor agonist and SGLT2 inhibitor on infection risk: network meta-analysis
Zeng, B.-S., Chen, J.-J., Hsu, C.-W., Hung, C.-M., Zeng, B., Suen, M., Yang, W.-C., Wang, H.-Y., Shiue, Y.-L., Su, K.-P., et al. (2026) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2026.01.014 · Cited by 8
Ho, M. J., Liew, C. F., Tan, N. A. M. R., Morita, A., & Oon, H. H. B. (2026) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2026.2665732 · Cited by 8
Elangovan, H., Gunton, J. E., Zheng, M., Fan, J.-G., Goh, G. B., Grønbæk, H., & George, J. (2025) · Hepatology International · doi:10.1007/s12072-025-10795-6 · Cited by 7
Katz, G. (2025) · Hormone and Metabolic Research · doi:10.1055/a-2569-7315 · Cited by 7
Glucagon-like peptide-1 receptor agonists: What ophthalmologists need to know
Bala, S., Allan, K. C., Decker, N. L., Abbass, N. J., Joo, J. H., Zhao, A., Talcott, K. E., & Rachitskaya, A. V. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.12.007 · Cited by 7
Hu, S., Wang, S., Qi, C., Gu, S., Shi, C., Mao, L., & Fan, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.831364 · Cited by 7
Abordaje práctico de la semaglutida en el paciente con diabetes tipo 2
Escobar, C., Castro, A., Cerezo, J. F. G., Górriz, J. L., Obaya, J. C., & Villar‐Taibo, R. (2022) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(22)00013-9 · Cited by 7
Karavia, E. A., Giannopoulou, P. C., Konstantinopoulou, V., Athanasopoulou, K., Filippatos, T. D., Panagiotakos, D. B., & Kypreos, K. E. (2023) · Nutrients · doi:10.3390/nu15030606 · Cited by 7
Advances in incretin therapies for targeting cardiovascular disease in diabetes
Roberts, T. D., Hutchinson, D. S., Wootten, D. L., Blasio, M. J. D., & Ritchie, R. H. (2025) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2025.03.007 · Cited by 7
Rasalam, R. R., Abdo, S., Deed, G., O’Brien, R. C., & Overland, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14953 · Cited by 7
Lopes, A. C., Roque, F., Lourenço, O. M., Herdeiro, M. T., & Morgado, M. (2023) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2023.2172159 · Cited by 7
[editor], D. M. (2025) · Australasian anaesthesia · doi:10.60115/11055/1305 · Cited by 7
Taylor, S. I., Montasser, M. E., Yuen, A. H., Fan, H., Yazdi, Z. S., Whitlatch, H. B., Mitchell, B. D., Shuldiner, A. R., Muniyappa, R., Streeten, E. A., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15143 · Cited by 6
Glucagon-Like Peptide-1 Agonist Use in Adults With Congenital Heart Disease
Thapa, R., Lara-Breitinger, K. M., López-Jiménez, F. A., Shama, N., Egbe, A. C., Miranda, W. R., Connolly, H. M., Jain, C. C., Jokhadar, M., Kosec, A. M., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101674 · Cited by 6
Sedrak, P., Verma, R., Verma, M., & Connelly, K. A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.03.037 · Cited by 6
Vujosevic, S., Toma, C., Ferrulli, A., Cillà, S. D., Nucci, P., & Luzi, L. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02552-w · Cited by 6
Buse, J. B., Christensen, H. N., Harty, B. J., Cziraky, M. J., Willey, V. J., & Skibsted, S. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2025-005161 · Cited by 6
Diáz, R. D., Barrera, E. C., Fosado, L. A. D., Esparza, A. R., & Benitez, O. A. P. (2025) · Cureus · doi:10.7759/cureus.99865 · Cited by 6
Ridge, T. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000114 · Cited by 6
Lv, L., Wang, Y., Xie, L., Noone, J. M., Alvarez, S., Zhang, Y., Song, Y., & Rotroff, D. M. (2025) · Value in Health · doi:10.1016/j.jval.2025.01.018 · Cited by 6
Cañas, J. M. H., Pontificia Universidad Javeriana, B., Gómez-Gutiérrez, M., Pontificia Universidad Javeriana, B., Ossa, A. B., & Pontificia Universidad Javeriana, B. (2023) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2023.19.2.4 · Cited by 6
Kroopnick, J. M., & Davis, S. N. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2089021 · Cited by 6
Yami, M. S. A., Alfayez, O. M., & Alsheikh, R. (2018) · Heart Lung and Circulation · doi:10.1016/j.hlc.2018.03.018 · Cited by 6
Prieto, B. L. A., & Lozano, E. W. M. (2001) · Repositorio Institucional Universidad Católica de Colombia (Universidad Católica de Colombia) · Cited by 6
Coke, L. A., DEEDWANIA, P. C., Hinnen, D., Magwire, M., & Miller, N. H. (2022) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000661 · Cited by 6
Weighing the Impacts of GLP-1s: Quasi-Experimental Evidence From Provider Adoption
Bock, S., Moshfegh, J., & Zhang, J. (2026) · National Bureau of Economic Research · doi:10.3386/w34667 · Cited by 6
Ayesh, H., Suhail, S., Ayesh, S. K., & Niswender, K. D. (2024) · Biomedicines · doi:10.3390/biomedicines12091943 · Cited by 5
Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations
Li, Y., Xue, K., Hu, R., Hu, X., Guo, R., Hongxia, G., & Li, G. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00738-9 · Cited by 5
Drygalski, K., Pastuszak, K., & Modzelewska, B. (2025) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.17141 · Cited by 5
Abusedera, O., Sherif, J., Smida, M., & Fredericks, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14248734 · Cited by 5
Rabbani, S. A., Saini, M., El-Tanani, M. E.-T., Kumar, R., Matalka, I. I., El‐Tanani, Y., Sharma, S., & Rizzo, M. (2026) · Pharmaceuticals · doi:10.3390/ph19050732 · Cited by 5
Abdelmannan, D. K., AlBuflasa, M., Ajlouni, H. K., Zidan, M. A., Rahman, F., Farooqi, M. H., & Caballero, A. E. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111045 · Cited by 5
[Glucagon-like peptide 1 receptor agonists for the treatment of Type 2 diabetes].
Andersen, A., Christensen, A. S., Knop, F. K., & Vilsbøll, T. (2019) · Research at the University of Copenhagen (University of Copenhagen) · Cited by 5
Pathophysiologic Approach to Type 2 Diabetes Management: One Centre Experience 1980–2020
Chlup, R., Kaňa, R., Hanáčková, L., Zálešáková, H., & Doubravová, B. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96237 · Cited by 5
Ares, J., Pujante, P., Lambert, C., Morales-Sánchez, P., Delgado-Álvarez, E., & Torre, E. L. M. (2022) · Revista Clínica Española · doi:10.1016/j.rce.2022.03.009 · Cited by 5
Vitorino, R. M. P. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14334 · Cited by 5
Tan, X., Liang, Y. M., Gamble, C. L., & King, A. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01509-y · Cited by 5
Once-weekly GLP-1R agonists: moving the goal posts
Tahrani, A. A., Bellary, S., & Barnett, A. H. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30049-4 · Cited by 5
Wang, J., Jin, X., An, P., Yu, S., & Mu, Y. (2019) · Journal of Diabetes Research · doi:10.1155/2019/8083417 · Cited by 5
Samad, A. R., Rajpoot, N. N., Ayaz, H., & Sadiq, N. (2019) · Journal of Bahria University Medical and Dental College · doi:10.51985/jbumdc2018125 · Cited by 5
Gronroos, N. N., Swift, C., Frazer, M., Sargent, A., Leszko, M., Buysman, E. K., Alvarez, S., Dunn, T. J., & Noone, J. M. (2024) · Journal of health economics and outcomes research · doi:10.36469/001c.124111 · Cited by 4
Person Centered Approach and Challenges in the Management of Obesity
Garcha, S. C., & Kalra, S. (2025) · Springer eBooks · doi:10.1007/978-981-96-1651-0_7 · Cited by 4
Kassem, S., Khalaila, B., Stein, N., & Zaina, A. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i11.112999 · Cited by 4
Ng, M. K., Mastrokostas, P. G., Rodriguez, A. N., Razi, A., Mastrokostas, L. E., Emara, A. K., Ford, B. T., Xu, J. J., Dalton, J., Narayanan, R., et al. (2025) · Journal of Craniovertebral Junction and Spine · doi:10.4103/jcvjs.jcvjs_156_25 · Cited by 4
Kumar, S. R., Anderson, J. E., Coviello, A. D., Lopez-Jimenez, F., & Bakris, G. L. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102465 · Cited by 4
Srisurapanont, M., Suttajit, S., Likhitsathian, S., Suradom, C., & Maneeton, B. (2026) · The International Journal of Psychiatry in Medicine · doi:10.1177/00912174261422822 · Cited by 4
Ng, M. K., Mastrokostas, P. G., Tabbaa, A., Razi, A., Johnson, M., Said, M., Mastrokostas, L. E., Dalton, J., Vaccaro, A. R., Kepler, C. K., et al. (2026) · Orthopedics · doi:10.3928/01477447-20251219-01 · Cited by 4
Kim, D.-H., Hwang, S.-K., Yoon, J.-H., Na, D. H., Park, Y.-J., Chae, Y., Chang, J., & Kim, J.-E. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18060680 · Cited by 4
Semaglutida en enfermedad renal diabética: Experiencia en dos programas de salud renal en Colombia
Daza-Arnedo, R., Rico-Fontalvo, J. E., Raad-Sarabia, M., Clason, E. C. R., Bohórquez-Rivero, J., Montejo-Hernández, J. D., Cabrales, J., Escobar-Pacheco, C., Pérez, T. A. A., Henao-Ramirez, C., et al. (2022) · Revista Colombiana de Endocrinología Diabetes & Metabolismo · doi:10.53853/encr.9.3.776 · Cited by 4
Cohen, C. M., Mosenzon, O., Aharonovich, A., Karasik, A., & Schechter, M. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112086 · Cited by 4
Amamoo, J. J., Doshi, R., Noone, J., Xie, L. Y., Gamble, C. L., Guevarra, M., Divino, V. M., Chen, J., & King, A. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01721-y · Cited by 4
Agonistas de GLP-1 en el control glucémico y ponderal de la diabetes tipo 2. Nuevas perspectivas
Alonso, S. P., Valdés, S., & Doulatram‐Gamgaram, V. K. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107042 · Cited by 4
Kobalava, Z. D., & Кохан, Е. В. (2020) · Kardiologiia · doi:10.18087/cardio.2020.9.n1274 · Cited by 4
Ares, J., Pujante, P., Lambert, C., Morales-Sánchez, P., Delgado-Álvarez, E., & Torre, E. L. M. (2022) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2022.06.001 · Cited by 4
Frazer, M., Swift, C., Sargent, A., Leszko, M., Buysman, E. K., Gronroos, N. N., Alvarez, S., Dunn, T. J., Noone, J. M., & Gamble, C. L. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01341-y · Cited by 4
Oral semaglutide effectiveness and safety in real world practice; The REVOLUTION study
Alsheikh, A., Alshehri, A., ALZAHRANI, S. H., Jammah, A. A., Alqahtani, F., Alotaibi, M. S., Aldahash, R., Alhozali, A. M., Alsabaan, F., Almehthel, M. S., et al. (2024) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2024.100209 · Cited by 4
Preoperative Assessment of a Patient Undergoing Bariatric Surgery
Yuan, J. J., Bangalore, R., Darwish, D., Moon, T. S., & Wadhwa, A. N. (2023) · Anesthesiology Clinics · doi:10.1016/j.anclin.2023.07.005 · Cited by 4
Antidiabetic Effect of Abextide, a Long‐Acting Exendin‐4 Analogue in Cynomolgus Monkeys
Niu, G., Wang, G., Lau, J., Lang, L., Jacobson, O., Ma, Y., Kiesewetter, D. O., Zhang, S., & Chen, X. S. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800686 · Cited by 4
Tsai, C.-J., & Tsao, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12111915 · Cited by 4
Rudofsky, G., Menzen, M., Potier, L., Catarig, A.-M., Clark, A., Priyadarshini, P., & Abreu, C. (2025) · Advances in Therapy · doi:10.1007/s12325-024-03000-x · Cited by 3
“There were no new safety concerns with OW semaglutide, which is in keeping with data from the SUSTAIN clinical trials and the gen‑ eral population of the first four SURE studies [4–12 , As a single‑armed, non‑interventional study, there are some limitations to this analysis.”
InfluentialSemaglutide in Diabetic Kidney Disease: Integrating Clinical Evidence with Mechanistic Insights
Dayel, F. F. B. (2025) · Healthcare · doi:10.3390/healthcare13222922 · Cited by 3
Ko, D., Kim, D. H., Tan, F. X. N., Ho, G. J. K., Chandra, R., Xuan, Z. Z., Tham, E. K. J., Tang, N. S. Y., Yang, H. S., Koh, J. W. H., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102614 · Cited by 3
Glucagon-like peptide-1 drugs, gastrointestinal function and critical illness
Nadkarni, A., Deane, A. M., & Plummer, M. P. (2026) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001376 · Cited by 3
Pharmacologic Treatment of Obesity in the Context of Type 2 Diabetes
Conte, C., & Amaro, A. (2026) · Current Diabetes Reports · doi:10.1007/s11892-026-01626-5 · Cited by 3
Buonanno, S., Gaggiano, C., Baldi, C., Cantarini, L., Frediani, B., & Gentileschi, S. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16060284 · Cited by 3
Wharton, S., Stefański, A., Chen, J., Rao, G. S., Twum, E. A., & Denning, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71032 · Cited by 3
Vignera, S. L., & Condorelli, R. A. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag149 · Cited by 3
Are there differences in the efficacy of once-weekly GLP-1RAs in patients with type 2 diabetes?
Strong, J. L. (2018) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000113 · Cited by 3
Lingvay, I., Catarig, A., Lawson, J., Chubb, B., Gorst‐Rasmussen, A., & Evans, L. M. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01344-7 · Cited by 3
Self-citationEfficacy and Safety of Semaglutide in Weight Loss of Non-diabetic People
Song, C.-E., Wang, Y., Dai, X., & Wu, H. (2024) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303283400240521120048 · Cited by 3
Charting New Territories in Obesity Management- Traditional Techniques to Tirzepatide
Fareed, A., Ghanem, L., Vaid, R., Iftikhar, Z., Rehman, A. U., Sarwar, A., & Asif, M. I. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.09.004 · Cited by 4
Reconsidering Semaglutide Use for Chronic Obesity in Patients of Asian Descent: A Critical Review
Lu, J., Williams, G., & Fanning, S. (2024) · Cureus · doi:10.7759/cureus.73111 · Cited by 3
Goldenberg, R. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15588 · Cited by 3
Ji, L., Lu, Y., Shen, Z., Hu, P., Liu, W., Zhang, Q., & Shi, B. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15888 · Cited by 3
Ding, L., Sun, B., Xiao, X., & Kin, T. (2020) · International Journal of Endocrinology · doi:10.1155/2020/1626484 · Cited by 3
Newer Glucose-Lowering Medications and Potential Role in Metabolic Management of PCOS
Anam, A. K., & Inzucchi, S. E. (2022) · Springer eBooks · doi:10.1007/978-3-030-92589-5_26 · Cited by 3
Шамхалова, М. Ш., & Shestakova, M. V. (2022) · Diabetes Mellitus · doi:10.14341/dm12941 · Cited by 3
Milenković, T., Mitreva, B. C., Mishevska, S. J., Bitoska-Mileva, I., & Ahmeti, I. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.111018 · Cited by 3
Efficacy of newer agents in the glycaemic management of patients with type 2 diabetes
Chudleigh, R. A., & Bain, S. C. (2019) · Current Medical Research and Opinion · doi:10.1080/03007995.2019.1678344 · Cited by 3
Makunts, T., Joulfayan, H., & Abagyan, R. (2023) · PubMed Central · doi:10.1101/2023.11.19.23298750 · Cited by 3
Qureshy, K., Kirk, A. R., Wolden, M. L., Zonoozi, A. A. M., & Liu, A. (2022) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000260 · Cited by 2
AN OVERVIEW OF INCRETIN-BASED THERAPIES: PHARMACOLOGY AND FUTURE PERSPECTIVES
Ismail, R., Anter, A. F., Matouk, A. I., & Heeba, G. H. (2022) · Bulletin of Pharmaceutical Sciences Assiut · doi:10.21608/bfsa.2022.160122.1493 · Cited by 2
Efeitos da liraglutida em pacientes com diabetes tipo 2 e obesidade
de Fraga, B. C., & Deuner, M. C. (2024) · Revista JRG de Estudos Acadêmicos · doi:10.55892/jrg.v7i14.1156 · Cited by 2
The Impact of Semaglutide on Metabolic Syndrome: A Case Report
Joseph, J. (2025) · Cureus · doi:10.7759/cureus.87223 · Cited by 2
Iwata, Y., Yoshikawa, F., Saito, M., Fuchigami, A., Sato, G. E., Saiki, A., Ichijyo, T., Sato, N., Ohashi, T., Hirose, T., et al. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01790-z · Cited by 2
Meng, F. X., Ao, X., Lin, X., Li, Y., Zhang, R., Yu, Z., Zang, S., & Sun, T. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70524 · Cited by 2
Butt, M. D., Hussain, A., & Ong, S. C. (2026) · Journal of Pharmaceutical Policy and Practice · doi:10.1080/20523211.2026.2631932 · Cited by 2
Differential Acute Kidney Injury Profiles of GLP-1RAs and SGLT2is: A Network Meta-Analysis
Liang, C.-S., Hsu, C.-C., Chen, J.-J., Hung, C.-M., Zeng, B., Yang, W.-C., Suen, M., Wang, H.-Y., Carvalho, A. F., Stubbs, B., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27094137 · Cited by 2
Builes-Montaño, C. E., Suarez-Rodriguez, A. F., & Alzate-Vinasco, M. A. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01886-0 · Cited by 2
Exercise modulates food reward: neurobiological mechanisms and implications for weight management
Qiu, J., Ji, P., Dai, X., Qiu, D., Fang, Q., Li, Y., Che, T., Qiu, F., & Zhang, S. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1845848 · Cited by 2
Cohan, C. S., Townley, L., & Ortega, E. (2026) · Case Reports in Neurology · doi:10.1159/000552961 · Cited by 2
Xiao-yu, Z., Wu, Q., Lu, H.-L., Xie, J.-J., Zhang, Y., Xu, Y., Guo, M., & Teng, F. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02163-7 · Cited by 2
Kim, J.-M., Kim, K., Yu, N.-Y., Kim, D., Kang, J. Y., Baek, S.-K., Park, J., & Park, J. Y. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18070770 · Cited by 2
Ji, L., Andersen, J. S., Benamar, M., Ponzani, P., Unnikrishnan, A. G., VINTHER, S. M., & Rea, R. R. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70895 · Cited by 2
Ji, L., Benamar, M., Mohan, V., Pletsch‐Borba, L., Porcellati, F., Wang, N., Watada, H., & Rea, R. R. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00136-1 · Cited by 2
Beyond Weight Loss: Skeletal Muscle Health During Incretin-Based Therapy in Patients with Diabesity
Mollero, E. L. M., Dozzani, I., Biamonte, E., Bendotti, G., Marzullo, P., Aimaretti, G., & Gallo, M. (2026) · Nutrients · doi:10.3390/nu18162654 · Cited by 3
Semaglutide Bioavailability: Limitations, Formulation Innovation and Future Opportunities
Vahora, S., Shah, V., & Patel, B. (2026) · Pharmaceutical Research · doi:10.1007/s11095-026-04185-2 · Cited by 2
Efficacy of semaglutide: an evidence-based review
Mkrtumyan, A. M., & Egshatyan, L. V. (2022) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2022-010 · Cited by 2
Kukova, L., Munir, K. M., Sayeed, A., & Davis, S. N. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2401589 · Cited by 3
Cárdenas‐Salas, J., Sierra-Poyatos, R., Luca, B. L., Sánchez-Lechuga, B., Móstoles, N. M., Álvarez, T. M., Montes, M. D. L. P. G., Ruiz-Sánchez, J. G., Meneses, D., Sánchez-Lopez, R., et al. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108874 · Cited by 2
Metadata
- Authors
- Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R.
- Affiliations
- Oregon Health & Science University (US)
- Rotherham Institute for Obesity, Clifton Medical Centre, Rotherham, U.K.
- Centre Hospitalier Sud Francilien (FR)
- University of Siena (IT)
- GWT-TUD GmbH (Germany) (DE)
- The University of Texas Southwestern Medical Center (US)
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk Inc., Plainsboro, NJ
- MedStar Health Research Institute (US)
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2017-12-15
- Volume
- 41
- Issue
- 2
- Pages
- 258-266
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2774157762
- Cited by
- 596
- References
- 32
- Citations by year
- 2026: 57 · 2025: 91 · 2024: 88 · 2023: 68 · 2022: 68 · 2021: 48 · 2020: 64 · 2019: 55 · 2018: 51 · 2017: 3
- FWCI
- 37.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, exenatide extended-release, type 2 diabetes, GLP-1 receptor agonists, glycemic control, HbA1c, weight loss, gastrointestinal adverse effects, injection site reactions, non-inferiority, oral antidiabetic drugs, drug safety and efficacy comparison, weekly dosing
- MeSH terms
- Exenatide, Semaglutide, Adult, Aged, Aged, 80 and over, Blood Glucose, Body Weight, Delayed-Action Preparations, Diabetes Mellitus, Type 2, Drug Administration Schedule, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Venoms, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.